Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential
出版年份 2015 全文链接
标题
Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential
作者
关键词
-
出版物
Therapeutic Advances in Medical Oncology
Volume 8, Issue 1, Pages 4-31
出版商
SAGE Publications
发表日期
2015-12-23
DOI
10.1177/1758834015615514
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Update on Immune Checkpoint Inhibitors in Lung Cancer
- (2017) Benjamin C. Creelan Cancer Control
- Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses
- (2015) P. Mitchell et al. ANNALS OF ONCOLOGY
- Cancer Vaccines: Can They Improve Survival?
- (2015) Robert O. Dillman CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- Low-dose cyclophosphamide enhances antigen-specific CD4+ T cell responses to NY-ESO-1/ISCOMATRIX™ vaccine in patients with advanced melanoma
- (2015) Oliver Klein et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Abstract 285: MEDI9447: enhancing anti-tumor immunity by targeting CD73 In the tumor microenvironment
- (2015) Carl Hay et al. CANCER RESEARCH
- Abstract 2859: Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC)
- (2015) Leisha A. Emens et al. CANCER RESEARCH
- Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy
- (2015) A. Yonezawa et al. CLINICAL CANCER RESEARCH
- Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome
- (2015) D. GuhaThakurta et al. CLINICAL CANCER RESEARCH
- PD-1/PD-L1 inhibitors
- (2015) Joel Sunshine et al. CURRENT OPINION IN PHARMACOLOGY
- Nivolumab: A Review in Advanced Melanoma
- (2015) Lesley J. Scott DRUGS
- Disialoganglioside GD2 as a therapeutic target for human diseases
- (2015) Maya Suzuki et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Receptor tyrosine kinase-like orphan receptor 1: a novel target for cancer immunotherapy
- (2015) Mahdi Shabani et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Research progress of indoleamine 2,3-dioxygenase inhibitors
- (2015) Tianze Jiang et al. Future Medicinal Chemistry
- Development of PROSTVAC immunotherapy in prostate cancer
- (2015) Parminder Singh et al. Future Oncology
- Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial
- (2015) Nick Thatcher et al. LANCET ONCOLOGY
- Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study
- (2015) Luis Paz-Ares et al. LANCET ONCOLOGY
- Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy
- (2015) Abhisek Swaika et al. MOLECULAR IMMUNOLOGY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2
- (2015) Elizabeth A. Raetz et al. PEDIATRIC BLOOD & CANCER
- Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses
- (2015) Jun Liu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PD-L1 Blockade for Cancer Treatment: MEDI4736
- (2015) Ramy Ibrahim et al. SEMINARS IN ONCOLOGY
- PD-L1 Inhibition With MPDL3280A for Solid Tumors
- (2015) Edward Cha et al. SEMINARS IN ONCOLOGY
- Anti–PD-1 Therapy in Melanoma
- (2015) Blanca Homet Moreno et al. SEMINARS IN ONCOLOGY
- XAGE-1b Cancer/Testis Antigen Is a Potential Target for Immunotherapy in Prostate Cancer
- (2015) Chong Xie et al. UROLOGIA INTERNATIONALIS
- Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
- (2015) Baoan Chen et al. Drug Design Development and Therapy
- Immunological response and overall survival in a subset of advanced renal cell carcinoma patients from a randomized phase 2/3 study of naptumomab estafenatox plus IFN-α versus IFN-α
- (2015) Eyad Elkord et al. Oncotarget
- Tim-3 and Tim-4 as the potential targets for antitumor therapy
- (2015) Lin Cheng et al. Human Vaccines & Immunotherapeutics
- Assessing the Effects of Concurrent versus Sequential Cisplatin/Radiotherapy on Immune Status in Lung Tumor-Bearing C57BL/6 Mice
- (2015) C.-J. Kao et al. Cancer Immunology Research
- Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells
- (2015) B. Boyerinas et al. Cancer Immunology Research
- Review of the Results of WT1 Peptide Vaccination Strategies for Myelodysplastic Syndromes and Acute Myeloid Leukemia from Nine Different Studies
- (2015) Antonio Di Stasi et al. Frontiers in Immunology
- Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation–positive non-small cell lung cancers: an update for recent advances in therapeutics
- (2015) Clement Chung JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer
- (2015) Christopher R. Heery et al. JAMA Oncology
- Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma
- (2015) Weiqing Jing et al. Journal for ImmunoTherapy of Cancer
- An updated overview of HPV-associated head and neck carcinomas
- (2015) Apostolos Zaravinos Oncotarget
- Novel antigens in non-small cell lung cancer: SP17, AKAP4, and PTTG1 are potential immunotherapeutic targets
- (2015) Leonardo Mirandola et al. Oncotarget
- Classification of current anticancer immunotherapies
- (2015) Lorenzo Galluzzi et al. Oncotarget
- A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors
- (2015) Hatem H. Soliman et al. Oncotarget
- Mylotarg has potent anti-leukaemic effect: a systematic review and meta-analysis of anti-CD33 antibody treatment in acute myeloid leukaemia
- (2014) J. Loke et al. ANNALS OF HEMATOLOGY
- The Targeting of Indoleamine 2,3 Dioxygenase -Mediated Immune Escape in Cancer
- (2014) Trine Zeeberg Iversen et al. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
- Current status of antibody therapy in ALL
- (2014) Jing Ai et al. BRITISH JOURNAL OF HAEMATOLOGY
- SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia
- (2014) Anjali S. Advani et al. BRITISH JOURNAL OF HAEMATOLOGY
- CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?
- (2014) Luana Calabrò et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Immunological response induced by abagovomab as a maintenance therapy in patients with epithelial ovarian cancer: relationship with survival—a substudy of the MIMOSA trial
- (2014) Alexia Buzzonetti et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors
- (2014) Volker Lennerz et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- VISTA Is an Immune Checkpoint Molecule for Human T Cells
- (2014) J. L. Lines et al. CANCER RESEARCH
- VISTA Regulates the Development of Protective Antitumor Immunity
- (2014) I. Le Mercier et al. CANCER RESEARCH
- Induction of Robust Type-I CD8+ T-cell Responses in WHO Grade 2 Low-Grade Glioma Patients Receiving Peptide-Based Vaccines in Combination with Poly-ICLC
- (2014) H. Okada et al. CLINICAL CANCER RESEARCH
- Phase II Clinical Trial of Multiple Peptide Vaccination for Advanced Head and Neck Cancer Patients Revealed Induction of Immune Responses and Improved OS
- (2014) Y. Yoshitake et al. CLINICAL CANCER RESEARCH
- A Randomized, Multicenter, Placebo-Controlled Clinical Trial of Racotumomab-Alum Vaccine as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients
- (2014) S. Alfonso et al. CLINICAL CANCER RESEARCH
- Adenosine A2A Receptor Antagonists in Parkinson’s Disease: Progress in Clinical Trials from the Newly Approved Istradefylline to Drugs in Early Development and Those Already Discontinued
- (2014) Annalisa Pinna CNS DRUGS
- Expression of cancer testis antigens CT10 (MAGE-C2) and GAGE in gastrointestinal stromal tumors
- (2014) T. Ghadban et al. EJSO
- Wilms' tumor gene 1 immunotherapy in pelvic gynecological malignancies
- (2014) A Coosemans et al. Expert Review of Clinical Immunology
- Shaping the repertoire of tumor-infiltrating effector and regulatory T cells
- (2014) Peter A. Savage et al. IMMUNOLOGICAL REVIEWS
- PROSTVAC® targeted immunotherapy candidate for prostate cancer
- (2014) Neal D Shore Immunotherapy
- NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virus
- (2014) Ji-Li Chen et al. INTERNATIONAL JOURNAL OF CANCER
- Survivin as a Preferential Target for Cancer Therapy
- (2014) Mahsa Mobahat et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- A peptide antigen derived from EGFR T790M is immunogenic in non-small cell lung cancer
- (2014) KAZUYA OFUJI et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Telomerase (GV1001) vaccination together with gemcitabine in advanced pancreatic cancer patients
- (2014) CAROLINE STAFF et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Estimating the Value of Intravenous Calcium and Magnesium in Ameliorating Oxaliplatin-Induced Neuropathy
- (2014) Carl D. Atkins JOURNAL OF CLINICAL ONCOLOGY
- Antigen-Specific Immune Responses and Clinical Outcome After Vaccination With Glioma-Associated Antigen Peptides and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Children With Newly Diagnosed Malignant Brainstem and Nonbrainstem Gliomas
- (2014) Ian F. Pollack et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
- (2014) Eric Pujade-Lauraine et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831
- (2014) Edith A. Perez et al. JOURNAL OF CLINICAL ONCOLOGY
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Expression of cancer-testis antigen in multiple myeloma
- (2014) Li He et al. Journal of Huazhong University of Science and Technology-Medical Sciences
- Alternative Activation of Human Plasmacytoid DCs In Vitro and in Melanoma Lesions: Involvement of LAG-3
- (2014) Chiara Camisaschi et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial
- (2014) Emanuela Romano et al. Journal of Translational Medicine
- Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
- (2014) Edward B Garon et al. LANCET
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- (2014) Caroline Robert et al. LANCET
- Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study
- (2014) Timothy J Price et al. LANCET ONCOLOGY
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
- (2014) Hansjochen Wilke et al. LANCET ONCOLOGY
- NY-ESO-1 (CTAG1B) expression in mesenchymal tumors
- (2014) Makoto Endo et al. MODERN PATHOLOGY
- MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress
- (2014) Mildred Felder et al. Molecular Cancer
- A vaccine targeting mutant IDH1 induces antitumour immunity
- (2014) Theresa Schumacher et al. NATURE
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- Therapeutic vaccines for cancer: an overview of clinical trials
- (2014) Ignacio Melero et al. Nature Reviews Clinical Oncology
- Improved Survival with Bevacizumab in Advanced Cervical Cancer
- (2014) Krishnansu S. Tewari et al. NEW ENGLAND JOURNAL OF MEDICINE
- SPAG9 expression is increased in human prostate cancer and promotes cell motility, invasion and angiogenesis in vitro
- (2014) FEIFEI CHEN et al. ONCOLOGY REPORTS
- Pancreatic cancer counterattack: MUC4 mediates Fas-independent apoptosis of antigen-specific cytotoxic T lymphocyte
- (2014) YI ZHU et al. ONCOLOGY REPORTS
- Novel cancer-testis antigen expression on glioma cell lines derived from high-grade glioma patients
- (2014) YASUTO AKIYAMA et al. ONCOLOGY REPORTS
- Cancer/Testis Antigen HCA587-Derived Long Peptide Vaccine Generates Potent Immunologic Responses and Antitumor Effects in Mouse Model
- (2014) Lijie Zhang et al. ONCOLOGY RESEARCH
- The receptor tyrosine kinase ROR1 – An oncofetal antigen for targeted cancer therapy
- (2014) Mohammad Hojjat-Farsangi et al. SEMINARS IN CANCER BIOLOGY
- Understanding and exploiting 5T4 oncofoetal glycoprotein expression
- (2014) Peter L. Stern et al. SEMINARS IN CANCER BIOLOGY
- Immunotherapeutic Agents in Non-small-cell Lung Cancer Finally Coming to the Front Lines
- (2014) Rossana Ruiz et al. Current Oncology Reports
- Naptumomab Estafenatox: Targeted Immunotherapy with a Novel Immunotoxin
- (2014) Tim Eisen et al. Current Oncology Reports
- Cancer-testis antigen MAGE-C2/CT10 induces spontaneous CD4+ and CD8+ T-cell responses in multiple myeloma patients
- (2014) H Reinhard et al. Blood Cancer Journal
- TroVax in colorectal cancer
- (2014) Julie Rowe et al. Human Vaccines & Immunotherapeutics
- Tecemotide: An antigen-specific cancer immunotherapy
- (2014) Gregory T Wurz et al. Human Vaccines & Immunotherapeutics
- Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor-Modified T Cells
- (2014) C. Berger et al. Cancer Immunology Research
- VISTA Is a Novel Broad-Spectrum Negative Checkpoint Regulator for Cancer Immunotherapy
- (2014) J. L. Lines et al. Cancer Immunology Research
- Antitumor Effects of Cisplatin Combined with Tecemotide Immunotherapy in a Human MUC1 Transgenic Lung Cancer Mouse Model
- (2014) C.-J. Kao et al. Cancer Immunology Research
- Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
- (2014) F. S. Hodi et al. Cancer Immunology Research
- Tim-3: An Emerging Target in the Cancer Immunotherapy Landscape
- (2014) A. C. Anderson Cancer Immunology Research
- EBAG9 modulates host immune defense against tumor formation and metastasis by regulating cytotoxic activity of T lymphocytes
- (2014) T Miyazaki et al. Oncogenesis
- Novel agents in development for advanced non-small cell lung cancer
- (2014) Thomas E. Stinchcombe Therapeutic Advances in Medical Oncology
- Trial Watch
- (2014) Erika Vacchelli et al. OncoImmunology
- Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy
- (2014) Jing Lu et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Blinatumomab, a Bi-Specific Anti-CD19/CD3 BiTE® Antibody for the Treatment of Acute Lymphoblastic Leukemia: Perspectives and Current Pediatric Applications
- (2014) Lindsey M. Hoffman et al. Frontiers in Oncology
- A Randomized Phase II Study of Immunization With Dendritic Cells Modified With Poxvectors Encoding CEA and MUC1 Compared With the Same Poxvectors Plus GM-CSF for Resected Metastatic Colorectal Cancer
- (2013) Michael A. Morse et al. ANNALS OF SURGERY
- Cause and Consequence of Cancer/Testis Antigen Activation in Cancer
- (2013) Angelique W. Whitehurst Annual Review of Pharmacology and Toxicology
- Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies
- (2013) H. E. Kohrt et al. BLOOD
- Developing an effective breast cancer vaccine: Challenges to achieving sterile immunity versus resetting equilibrium
- (2013) Giuseppe Curigliano et al. BREAST
- Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis
- (2013) Nicole Beauchemin et al. CANCER AND METASTASIS REVIEWS
- Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients
- (2013) Michael A. Morse et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Vaccination of castration-resistant prostate cancer patients with TroVax (MVA–5T4) in combination with docetaxel: a randomized phase II trial
- (2013) Richard Harrop et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen-Specific CD8+ T Cells Induced by Melanoma Vaccines
- (2013) J. Fourcade et al. CANCER RESEARCH
- Long-lasting Disease Stabilization in the Absence of Toxicity in Metastatic Lung Cancer Patients Vaccinated with an Epitope Derived from Indoleamine 2,3 Dioxygenase
- (2013) T. Z. Iversen et al. CLINICAL CANCER RESEARCH
- CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma
- (2013) André Veillette et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Phase I clinical trial of vaccination with LY6K-derived peptide in patients with advanced gastric cancer
- (2013) Hajime Ishikawa et al. Gastric Cancer
- Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
- (2013) Antoni Ribas et al. JOURNAL OF CLINICAL ONCOLOGY
- Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma
- (2013) Wim H.J. Kruit et al. JOURNAL OF CLINICAL ONCOLOGY
- Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial
- (2013) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant MAGE-A3 Immunotherapy in Resected Non–Small-Cell Lung Cancer: Phase II Randomized Study Results
- (2013) Johan Vansteenkiste et al. JOURNAL OF CLINICAL ONCOLOGY
- Predictive Gene Signature in MAGE-A3 Antigen-Specific Cancer Immunotherapy
- (2013) Fernando Ulloa-Montoya et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer
- (2013) David R. Spigel et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy
- (2013) Richard A. Morgan et al. JOURNAL OF IMMUNOTHERAPY
- Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
- (2013) Charles S Fuchs et al. LANCET
- Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial
- (2013) Luana Calabrò et al. LANCET ONCOLOGY
- Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial
- (2013) Charles Butts et al. LANCET ONCOLOGY
- Clinical significance and biological roles of SPAG9 overexpression in non-small cell lung cancer
- (2013) Yan Wang et al. LUNG CANCER
- Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer
- (2013) Jean-Louis Pujol et al. LUNG CANCER
- New checkpoint inhibitors ride the immunotherapy tsunami
- (2013) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Identification of HLA-A2 or HLA-A24-restricted CTL epitopes for potential HSP105-targeted immunotherapy in colorectal cancer
- (2013) YU SAWADA et al. ONCOLOGY REPORTS
- EGFR T790M Mutation as a Possible Target for Immunotherapy; Identification of HLA-A*0201-Restricted T Cell Epitopes Derived from the EGFR T790M Mutation
- (2013) Teppei Yamada et al. PLoS One
- Expression of the cancer-testis antigen BORIS correlates with prostate cancer
- (2013) Zubair Cheema et al. PROSTATE
- Antibody Therapeutics in Cancer
- (2013) M. X. Sliwkowski et al. SCIENCE
- Survival Advantage in Patients with Metastatic Breast Cancer Receiving Endocrine Therapy plus Sialyl Tn-KLH Vaccine: Post Hoc Analysis of a Large Randomized Trial
- (2013) Nuhad K. Ibrahim et al. Journal of Cancer
- The novel cancer-testis antigen A-kinase anchor protein 4 (AKAP4) is a potential target for immunotherapy of ovarian serous carcinoma
- (2013) Sumit Agarwal et al. OncoImmunology
- Expression of cell adhesion molecules and prognosis in breast cancer
- (2012) S. Saadatmand et al. BRITISH JOURNAL OF SURGERY
- Immunotherapy of cancer in 2012
- (2012) John M. Kirkwood et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma
- (2012) Jürgen C. Becker et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-cell Proliferation in Colorectal Cancer
- (2012) M. Terme et al. CANCER RESEARCH
- Cancer-testis antigen BORIS is a novel prognostic marker for patients with esophageal cancer
- (2012) Koji Okabayashi et al. CANCER SCIENCE
- Rationale and Design of MARQUEE: A Phase III, Randomized, Double-Blind Study of Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Patients With Locally Advanced or Metastatic, Nonsquamous, Non–Small-Cell Lung Cancer
- (2012) Giorgio V. Scagliotti et al. Clinical Lung Cancer
- Vaccines in non-small cell lung cancer: Rationale, combination strategies and update on clinical trials
- (2012) Tommaso De Pas et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Mucin-based Targeted Pancreatic Cancer Therapy
- (2012) Maria P. Torres et al. CURRENT PHARMACEUTICAL DESIGN
- Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials
- (2012) Carsten Bokemeyer et al. EUROPEAN JOURNAL OF CANCER
- MUC1 immunotherapy is here to stay
- (2012) Takashi Kimura et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Combination strategies to enhance antitumor ADCC
- (2012) Holbrook E Kohrt et al. Immunotherapy
- IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma
- (2012) Zhi-Zhang Yang et al. JOURNAL OF CLINICAL INVESTIGATION
- Safety and Immunogenicity of Vaccination With MART-1 (26–35, 27L), gp100 (209–217, 210M), and Tyrosinase (368–376, 370D) In Adjuvant With PF-3512676 and GM-CSF In Metastatic Melanoma
- (2012) Ahmad A. Tarhini et al. JOURNAL OF IMMUNOTHERAPY
- Long-term Tumor Regression Induced by an Antibody-Drug Conjugate That Targets 5T4, an Oncofetal Antigen Expressed on Tumor-Initiating Cells
- (2012) P. Sapra et al. MOLECULAR CANCER THERAPEUTICS
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- TIM-3 Expression Characterizes Regulatory T Cells in Tumor Tissues and Is Associated with Lung Cancer Progression
- (2012) Xin Gao et al. PLoS One
- Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients
- (2012) K. Odunsi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Carcinoembryonic Antigen (CEA)-Based Cancer Vaccines: Recent Patents and Antitumor Effects from Experimental Models to Clinical Trials
- (2012) Mario Turriziani et al. Recent Patents on Anti-Cancer Drug Discovery
- Immunotherapy Against HPV16/18 Generates Potent TH1 and Cytotoxic Cellular Immune Responses
- (2012) M. L. Bagarazzi et al. Science Translational Medicine
- The epithelial–mesenchymal transition under control: Global programs to regulate epithelial plasticity
- (2012) M. Angela Nieto et al. SEMINARS IN CANCER BIOLOGY
- CIMAvax EGF vaccine for stage IIIb/IV non-small cell lung carcinoma
- (2012) Jian Y. Cheng et al. Human Vaccines & Immunotherapeutics
- Novel Monoclonal Antibodies for Cancer Treatment: The Trifunctional Antibody Catumaxomab (Removab®)
- (2012) Diane Seimetz Journal of Cancer
- L-BLP25 vaccine plus letrozole for breast cancer
- (2012) Michael DeGregorio et al. OncoImmunology
- Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy
- (2011) Jean-Luc Brun et al. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
- Sperm-Associated Antigen 9 Is a Novel Biomarker for Colorectal Cancer and Is Involved in Tumor Growth and Tumorigenicity
- (2011) Deepika Kanojia et al. AMERICAN JOURNAL OF PATHOLOGY
- Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target
- (2011) R. Zappasodi et al. BLOOD
- Expression and Immunotherapeutic Targeting of the SSX Family of Cancer-Testis Antigens in Prostate Cancer
- (2011) H. A. Smith et al. CANCER RESEARCH
- Anti-TIM3 Antibody Promotes T Cell IFN- -Mediated Antitumor Immunity and Suppresses Established Tumors
- (2011) S. F. Ngiow et al. CANCER RESEARCH
- TroVax®vaccine therapy for renal cell carcinoma
- (2011) Rui-Tao Zhang et al. Immunotherapy
- Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
- (2011) Paul F. Robbins et al. JOURNAL OF CLINICAL ONCOLOGY
- Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31
- (2011) Edith A. Perez et al. JOURNAL OF CLINICAL ONCOLOGY
- VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
- (2011) Li Wang et al. JOURNAL OF EXPERIMENTAL MEDICINE
- gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma
- (2011) Douglas J. Schwartzentruber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase III Multicenter Clinical Trial of the Sialyl-TN (STn)-Keyhole Limpet Hemocyanin (KLH) Vaccine for Metastatic Breast Cancer
- (2011) D. Miles et al. ONCOLOGIST
- Immunological Effects of Bevacizumab-Based Treatment in Metastatic Colorectal Cancer
- (2011) M. Manzoni et al. ONCOLOGY
- Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy
- (2011) J. Stagg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- Expression of tumor-specific antigen MAGE, GAGE and BAGE in ovarian cancer tissues and cell lines
- (2010) Shiqian Zhang et al. BMC CANCER
- Rational drug design: A GAGE derived peptide kills tumor cells
- (2010) Rupinder Kular et al. CANCER BIOLOGY & THERAPY
- Vaccination of Metastatic Renal Cancer Patients with MVA-5T4: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
- (2010) R. J. Amato et al. CLINICAL CANCER RESEARCH
- The CD4-like molecule LAG-3, biology and therapeutic applications
- (2010) Sophie Sierro et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
- (2010) Jean-Yves Douillard et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival
- (2010) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
- (2010) Kaori Sakuishi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Cross-trial Analysis of Immunologic and Clinical Data Resulting From Phase I and II Trials of MVA-5T4 (TroVax) in Colorectal, Renal, and Prostate Cancer Patients
- (2010) Richard Harrop et al. JOURNAL OF IMMUNOTHERAPY
- First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity
- (2010) Chrystelle Brignone et al. Journal of Translational Medicine
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer
- (2009) James L. Gulley et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Regulatory T-Cell-Mediated Attenuation of T-Cell Responses to the NY-ESO-1 ISCOMATRIX Vaccine in Patients with Advanced Malignant Melanoma
- (2009) T. Nicholaou et al. CLINICAL CANCER RESEARCH
- Identification of an HLA-A*0201-restrictive CTL epitope from MUC4 for applicable vaccine therapy
- (2009) Junli Wu et al. IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY
- Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
- (2009) Henry S. Friedman et al. JOURNAL OF CLINICAL ONCOLOGY
- Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia
- (2009) Gemma G. Kenter et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- (2009) Eric Van Cutsem et al. NEW ENGLAND JOURNAL OF MEDICINE
- A dendritic cell-based tumour vaccine for lung cancer: full-length XAGE-1b protein-pulsed dendritic cells induce specific cytotoxic T lymphocytesin vitro
- (2008) Q. Zhou et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Phase II Randomized Controlled Trial of an Epidermal Growth Factor Vaccine in Advanced Non–Small-Cell Lung Cancer
- (2008) Elia Neninger Vinageras et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemoimmunotherapy Reinduction With Epratuzumab in Children With Acute Lymphoblastic Leukemia in Marrow Relapse: A Children's Oncology Group Pilot Study
- (2008) Elizabeth A. Raetz et al. JOURNAL OF CLINICAL ONCOLOGY
- EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer
- (2008) Alberto F. Sobrero et al. JOURNAL OF CLINICAL ONCOLOGY
- Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
- (2008) Carsten Bokemeyer et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1
- (2008) Naomi N. Hunder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
- (2008) Jan B. Vermorken et al. NEW ENGLAND JOURNAL OF MEDICINE
- CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens
- (2008) L. G. Almeida et al. NUCLEIC ACIDS RESEARCH
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started